Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Vivek Yadav, an engineering manager from ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

The second movie adaptation offers a subtle but meaningful nod to 'The Wizard of Oz' — and a closing scene with Ariana Grande and Cynthia Erivo that longtime fans of the musical will appreciate. By ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

If you thought there was no possible way out for Claire Danes’ Aggie in the “The Beast in Me” finale episode, that was by design. Showrunner Howard Gordon — with whom Danes worked on “Homeland” — ...

SPOILER ALERT: This article contains major spoilers for Osgood Perkins‘ “Keeper,” now playing in theaters. Director Osgood Perkins has given us not one, but two twisted horror movies this year that ...

There's a huge twist at the ending of Emma Stone's new movie Bugonia, and it needs to be discussed. After being kidnapped and trapped in a basement for most of the film, things finally come to a head ...

Let's make this simple. You want to know if there are any mid- or post-credits scenes in Predator: Badlands; the answer is ‘not really.’ A title card flashes on ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...